GlassScriptPhysician profile
Richard P Senzer
NPI 1508961772
$7,049.62
in general payments reported to CMS, 2019-2025
24 companies · $838 in 2025
The $838 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $1,024 · 2021: $825 · 2022: $1,065 · 2023: $826 · 2024: $1,006 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,658 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,657.59 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,779.77 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,743.48 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $514.89 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $488.28 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $251.51 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.21 | 2021-2025 | |
| Amarin Pharma, INC. | $154.81 | 2019-2021 | |
| Exact Sciences Corporation | $141.73 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $141.61 | 2019-2022 | |
| Abbvie INC. | $126.11 | 2021-2024 | Vraylar |
| Lundbeck LLC | $70.09 | 2023-2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $68.02 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $66.82 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.36 | 2019-2021 | |
| Pfizer INC. | $50.81 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $42.18 | 2024-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $41.37 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Arbor Pharmaceuticals, INC. | $40.57 | 2020-2021 | |
| Abbott Laboratories | $32.58 | 2021-2022 | |
| Allergan, INC. | $26.63 | 2019 | |
| Genentech USA, INC. | $25.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.08 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.74 | 2021 | |
| Sanofi Pasteur INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Senzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.